🇺🇸 FDA

Drug profile · INN

cisplatin

CISPLATIN

approved
US status
approved
Patents linked
4
News articles
0

Quick answer

cisplatin (CISPLATIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN cisplatin
Brand CISPLATIN
Route INJECTION
Formulation INJECTABLE
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 11013740

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10272084

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8703756

    Synthetic procedure and cancer treatment with cisplatin derivatives

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7700134

    Prevention of cisplatin induced deafness

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is cisplatin?

cisplatin (CISPLATIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for cisplatin?

CISPLATIN is a marketed brand name for cisplatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cisplatin?

cisplatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.